Tay-Sachs Gene Therapy Consortium (IMAGE)

Boston College

Tay-Sachs Gene Therapy Consortium

Caption

Families devastated by the deadly neurodegenerative Tay-Sachs disease have funded the start-up of the international Tay-Sachs Gene Therapy Consortium, which is developing a gene therapy they hope to begin testing with humans in four years. The research is a top priority for Susan Kahn, executive director of the National Tay-Sachs & Allied Diseases Association, pictured here with Boston College Professor of Biology Tom Seyfried, a lead researcher with the consortium, which was just awarded a $3.5 million grant from the National Institutes of Health.

Credit

Boston College

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.